A federal health advisory panel voted 8-6 on Thursday, with one abstention, to recommend easing FDA peptides restrictions on injectable products such as BPC-157, TB-500 and KPV. The recommendation would move the Food and Drug Administration closer to allowing pharmacies to compound more of the products marketed for wellness and cosmetic uses if the agency accepts it.
The panel advised the FDA to drop current limits that bar pharmacies from producing those injectable peptides and to add them to the agency’s list of substances considered safe for pharmacy compounding. David Pope, the chief pharmacy officer of Xifin Pharmacy Solutions, voted yes and said, "I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist."
FDA peptides on Thursday
The vote was narrow, but it carried immediate regulatory weight because the panel’s advice goes to the FDA, which is not required to follow it even though it usually does. Before Thursday’s meeting, more than a half-dozen people with connections to the peptide industry were added to the panel, a detail that sharpened attention on how the recommendations were being formed.
Robert F Kennedy Jr has described himself as a "big fan" of peptides and has vowed to overturn FDA restrictions put in place under Joe Biden. The Thursday vote keeps that promise in view while leaving the agency to decide whether to adopt the panel’s recommendation.
Elizabeth Rebello at the panel
Elizabeth Rebello, a doctor at the University of Texas MD Anderson Center, pushed back during the discussion. She said, "I’m concerned we’re responding to a market-induced demand rather than a decision based in solid science."
That criticism landed against the backdrop of FDA staff scientists saying there was little data that BPC-157, TB-500 and the other chemicals can be safely used for medical purposes. The products discussed have also been promoted online for unproven uses, often in stacks, while the panel’s recommendation could widen pharmacy compounding and telehealth marketing if the FDA follows it.
On Friday’s peptide vote
The panel is scheduled to vote on three more peptides on Friday, extending the same review into a second day. For pharmacies and telehealth companies, the practical question now is whether the FDA keeps the current limits or accepts a recommendation that would open the door to broader access to injectable peptide products.
People seeking the products for wellness or cosmetic uses would see the biggest change if the FDA adopts the advice, because the agency’s list of substances considered safe for compounding would grow and pharmacies could produce more of them under that framework.
